Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

GT Biopharma (GTBP) Current Assets (2016 - 2021)

GT Biopharma (GTBP) has disclosed Current Assets for 12 consecutive years, with $35.8 million as the latest value for Q3 2021.

  • On a quarterly basis, Current Assets rose 4197.48% to $35.8 million in Q3 2021 year-over-year; TTM through Sep 2021 was $35.8 million, a 4197.48% increase, with the full-year FY2020 number at $5.7 million, up 1966.06% from a year prior.
  • Current Assets was $35.8 million for Q3 2021 at GT Biopharma, down from $39.6 million in the prior quarter.
  • In the past five years, Current Assets ranged from a high of $39.6 million in Q2 2021 to a low of $39000.0 in Q2 2017.
  • A 5-year average of $6.7 million and a median of $902000.0 in 2020 define the central range for Current Assets.
  • Peak YoY movement for Current Assets: crashed 97.28% in 2019, then skyrocketed 14603.72% in 2021.
  • GT Biopharma's Current Assets stood at $576000.0 in 2017, then soared by 116.49% to $1.2 million in 2018, then tumbled by 78.03% to $274000.0 in 2019, then surged by 1966.06% to $5.7 million in 2020, then soared by 532.36% to $35.8 million in 2021.
  • Per Business Quant, the three most recent readings for GTBP's Current Assets are $35.8 million (Q3 2021), $39.6 million (Q2 2021), and $27.6 million (Q1 2021).